Novel Health Strategies Presenting Nineteen Studies on Health Outcomes and Market Access Trends at ISPOR 18th Annual International Meeting in New Orleans

Share Article

Novel Health Strategies team selected for nineteen peer-reviewed presentations at ISPOR 2013.

Comparative effectiveness research and economic valuation are becoming critical for drug and device development and commercialization plan. For new product launches, it is becoming important to demonstrate total value proposition to payers, providers and patients. Novel Health Strategies' nineteen peer-reviewed presentations at ISPOR 2013 highlight these trends:

May 20, 2013: Monday

Meta-Analysis for Efficacy of Romiplostim for Treatment of ITP
Reimbursement and Market Access of MS Products in the US
Trends in Cost Effectiveness of High Budget Impact Products
--
May 21, 2013: Tuesday

PROs in Glaucoma A Systematic Review
PROs in Chronic Myeloid Leukemia: A Systematic Review
PROs in Castration-Resistant Prostate Cancer: A Systematic Review
Meta-Analysis of Etanercept for Psoriatic Arthritis
Cancer Drug Pricing Trends in the US and the UK (2011-2013)
Novel Reimbursement Models for Cancer Drug Market Access
Novel Electronic Pros Tool for Prostate Cancer Patients
Budget Impact Model for CTCL
Systematic Review of Anti-VEGF Therapies for Metastatic CRC
In-Patient Hospitalization Trends for CKD in The United States
--

May 22, 2013: Wednesday

Meta-Analysis of Dabigatran and Warfarin for Atrial Fibrillation
Trends in Use of Economic Evidence for Developing Clinical Guidelines
Review of France's Transparency Committee's 2011-2012 Assessments
Pricing and Reimbursement of Targeted Cancer Therapies in Russia
Biosimilars Pricing Dynamics in Big Five European Union Countries
Role of Subgroup Analyses for Health Technology Assessments

--

About Novel Health Strategies
Novel Health Strategies ("Novel") is an award winning team of experienced professionals with expertise in healthcare strategy, research, policy, publications, health economics and outcomes research, modeling, and pricing and market access. Novel Health team has led strategy projects for majority of top 50 pharmaceutical, biotech and device companies. Novel Health has a large network of internal and external stakeholders and has published several thought leading strategy perspectives. Novel Health has presented industry trends and perspectives at ISPOR, AMCP and BIO meetings.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Saurabh (Rob) Aggarwal
Visit website